Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies

NCT02091063 is registered in ClinicalTrials.gov with Jennifer Amengual as lead sponsor.

NCT NCT02091063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02091063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies
Lead sponsor
Jennifer Amengual
Phase
Phase 1/2
Overall status
Terminated
Start date
April 2, 2014
Completion date
May 5, 2019
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoid malignancies, lymphoma